Kennedy et al. (116) applied HER2-MRM to 119 FFPE and 96 frozen breast cancer biopsy samples, highlighting the potential to identify HER2-low expression (IHC 1+ or 2) cases for which emerging targeting compounds (trastuzumab-deruxtecan) show benefit (34). The gene discussed is ERBB2; the disease is breast carcinoma.